Talmadge E King

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, UCSF, 505 Parnassus Avenue, Room M994, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 177:75-81. 2008
  2. ncbi Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
    Talmadge E King
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0120, USA
    Lancet 374:222-8. 2009
  3. ncbi Idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, University of California, San Francisco, CA 94143 0120, USA
    Lancet 378:1949-61. 2011
  4. ncbi BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, Box 0120, San Francisco, CA 94143 0120, USA
    Am J Respir Crit Care Med 184:92-9. 2011
  5. ncbi Bosentan for idiopathic pulmonary fibrosis
    Talmadge E King
    University of California San Francisco, Department of Medicine, San Francisco, CA 94143 0120, USA
    Curr Opin Investig Drugs 9:1171-9. 2008
  6. ncbi Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function
    Brent W Kinder
    Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0564, USA
    Lung 188:143-9. 2010
  7. ncbi A multidimensional index and staging system for idiopathic pulmonary fibrosis
    Brett Ley
    Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, Box 0111, San Francisco, CA 94143, USA
    Ann Intern Med 156:684-91. 2012
  8. ncbi Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA 94110, USA
    Chest 127:171-7. 2005
  9. ncbi Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis
    Joyce S Lee
    Department of Medicine, University of California San Francisco, USA
    Am J Respir Crit Care Med 184:1390-4. 2011
  10. ncbi Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis
    Harold R Collard
    Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    Chest 125:2169-74. 2004

Detail Information

Publications51

  1. ncbi BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, UCSF, 505 Parnassus Avenue, Room M994, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 177:75-81. 2008
    ..Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment...
  2. ncbi Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
    Talmadge E King
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0120, USA
    Lancet 374:222-8. 2009
    ..We assessed whether treatment with interferon gamma-1b improved survival compared with placebo in patients with idiopathic pulmonary fibrosis and mild-to-moderate impairment of pulmonary function...
  3. ncbi Idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, University of California, San Francisco, CA 94143 0120, USA
    Lancet 378:1949-61. 2011
    ..In this Seminar, we review recent data on the clinical course, therapeutic options, and underlying mechanisms thought to be involved in the pathogenesis of idiopathic pulmonary fibrosis...
  4. ncbi BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, Box 0120, San Francisco, CA 94143 0120, USA
    Am J Respir Crit Care Med 184:92-9. 2011
    ..A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and health-related quality of life were observed...
  5. ncbi Bosentan for idiopathic pulmonary fibrosis
    Talmadge E King
    University of California San Francisco, Department of Medicine, San Francisco, CA 94143 0120, USA
    Curr Opin Investig Drugs 9:1171-9. 2008
    ..These observations are being investigated in the ongoing BUILD-3 trial...
  6. ncbi Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function
    Brent W Kinder
    Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0564, USA
    Lung 188:143-9. 2010
    ..These findings demonstrate the clinical importance of identifying UCTD in patients presenting with an "idiopathic" interstitial pneumonia...
  7. ncbi A multidimensional index and staging system for idiopathic pulmonary fibrosis
    Brett Ley
    Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, Box 0111, San Francisco, CA 94143, USA
    Ann Intern Med 156:684-91. 2012
    ..Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication, help guide management, and facilitate research...
  8. ncbi Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA 94110, USA
    Chest 127:171-7. 2005
    ..Idiopathic pulmonary fibrosis (IPF) is a devastating disease, yet validated, reliable criteria for evaluating patient response to therapies in clinical trials are lacking...
  9. ncbi Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis
    Joyce S Lee
    Department of Medicine, University of California San Francisco, USA
    Am J Respir Crit Care Med 184:1390-4. 2011
    ..Gastroesophageal reflux (GER) is highly prevalent in patients with idiopathic pulmonary fibrosis (IPF). Chronic microaspiration secondary to GER may play a role in the pathogenesis and natural history of IPF...
  10. ncbi Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis
    Harold R Collard
    Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    Chest 125:2169-74. 2004
    ....
  11. ncbi Current perspectives on the treatment of idiopathic pulmonary fibrosis
    Nicholas Walter
    San Francisco General Hospital, 1001 Potrero Avenue, Room 5H22, San Francisco, CA 94110, USA
    Proc Am Thorac Soc 3:330-8. 2006
    ..g., IFN-gamma1b, pirfenidone, N-acetylcysteine, coumadin, bosentan, or etanercept). This article examines the body of evidence supporting the current therapies and reviews the newer agents being tested in patients with IPF...
  12. ncbi Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians
    Harold R Collard
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, 5K1, San Francisco, CA 94110, USA
    Respir Med 101:2011-6. 2007
    ..These results suggest there is general consensus regarding the approach to diagnosis, but that there is no consensus about medical management in IPF...
  13. ncbi Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis
    Brent W Kinder
    Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Chest 133:226-32. 2008
    ..We hypothesized that baseline BAL fluid cell count differential (ie, elevated levels of neutrophils and eosinophils, or reduced levels of lymphocytes) would predict higher mortality among persons with IPF...
  14. ncbi Acute exacerbations of idiopathic pulmonary fibrosis
    Harold R Collard
    Department of Medicine, San Francisco General Hospital, University of California, USA
    Am J Respir Crit Care Med 176:636-43. 2007
    ..The potential pathobiological roles of infection, disordered cell biology, coagulation, and genetics are discussed, and future research directions are proposed...
  15. ncbi Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis
    Harold R Collard
    Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Health Sciences Center, 1400 Jackson Street, Room F107, Denver, CO 80206, USA
    Am J Respir Crit Care Med 168:538-42. 2003
    ..Evaluation of changes in clinical and physiological variables over 6 and 12 months may provide clinicians with more accurate prognostic information than baseline values alone...
  16. ncbi Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis
    Harold R Collard
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Am J Physiol Lung Cell Mol Physiol 299:L3-7. 2010
    ..Furthermore, they suggest that acute exacerbation of IPF has a distinct plasma biomarker profile from that of acute lung injury...
  17. ncbi Clinical advances in the diagnosis and therapy of the interstitial lung diseases
    Talmadge E King
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, CA 94110, USA
    Am J Respir Crit Care Med 172:268-79. 2005
    ..This article highlights some of the advances and changes in clinical practice that took place in the management of patients with interstitial lung diseases over the last century...
  18. ncbi Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?
    Brent W Kinder
    Department of Medicine, University of California School of Medicine, San Francisco, California, USA
    Am J Respir Crit Care Med 176:691-7. 2007
    ....
  19. ncbi Clinical problem-solving. Anchors away
    Carolyn S Calfee
    Department of Medicine, University of California, San Francisco, USA
    N Engl J Med 356:504-9. 2007
  20. ncbi Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis
    Joyce S Lee
    Department of Medicine at University of California, San Francisco, 505 Parnassus Avenue, Box 0111, San Francisco, CA 94143, USA Electronic address
    Respir Med 107:249-55. 2013
    ..The objective of this study was to determine the frequency and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis...
  21. ncbi Clinical course and prediction of survival in idiopathic pulmonary fibrosis
    Brett Ley
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Am J Respir Crit Care Med 183:431-40. 2011
    ..Finally, we will discuss challenges and future directions related to predicting survival in IPF...
  22. ncbi Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management
    Talmadge E King
    Interstitial Lung Disease Center, San Francisco General Hospital, San Francisco, CA 94110, USA
    Trans Am Clin Climatol Assoc 115:43-76; discussion 76-8. 2004
    ....
  23. ncbi Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility
    Mehrdad Arjomandi
    Department of Medicine, University of California, San Francisco, CA, USA
    J Occup Environ Med 52:647-52. 2010
    ..To study the prevalence of beryllium sensitization (BeS) and chronic beryllium disease (CBD) in a cohort of workers from a nuclear weapons research and development facility...
  24. ncbi Does chronic microaspiration cause idiopathic pulmonary fibrosis?
    Joyce S Lee
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Med 123:304-11. 2010
    ..Defining the role of chronic microaspiration in idiopathic pulmonary fibrosis is essential as it has potential clinical, pathobiological, and treatment implications for this deadly disease...
  25. ncbi Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern
    Eunice J Kim
    Division of Pulmonary and Critical CareMedicine, Department of Medicine, University of California at San Francisco, CA, USA
    Chest 136:1397-405. 2009
    ..In patients in whom the underlying pattern cannot be determined by HRCT scanning, surgical lung biopsy should be considered...
  26. ncbi Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus
    Brent W Kinder
    Division of Rheumatology, University of California San Francisco, 374 Parnassus Avenue, San Francisco, CA 94143, USA
    Arthritis Rheum 56:2679-86. 2007
    ....
  27. ncbi Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis
    Jason S Vourlekis
    Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA
    Am J Med 112:490-3. 2002
  28. ncbi Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis
    Rafael L Perez
    Pulmonary Division, Department of Medicine, Emory University, Atlanta Veterans Affairs Medical Center, Atlanta, GA 30033, USA
    Respiration 74:297-303. 2007
    ..Abnormalities of lung coagulation and fibrinolysis in sarcoidosis are thought to play a role in the pathogenesis of this disease...
  29. ncbi A critical assessment of treatment options for idiopathic pulmonary fibrosis
    Nirav R Shah
    Department of Medicine, New York University School of Medicine, New York, NY, USA
    Sarcoidosis Vasc Diffuse Lung Dis 22:167-74. 2005
    ....
  30. ncbi Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia
    Gary W Hunninghake
    Department of Medicine, University of Iowa and Veterans Administration Medical Center, Iowa City, IA 52242, USA
    Chest 124:1215-23. 2003
    ..To determine which clinical and radiologic findings are independently associated with a pathologic diagnosis of usual interstitial pneumonia (UIP)...
  31. ncbi Demystifying idiopathic interstitial pneumonia
    Harold R Collard
    Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, USA
    Arch Intern Med 163:17-29. 2003
    ....
  32. ncbi Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence
    David G Morris
    Interstitial Lung Disease Program, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94142 0854, USA
    Chest 124:929-35. 2003
    ..The chronic granulomatous inflammation of sarcoidosis has been hypothesized to depend on the CD4+ T-helper lymphocyte. HIV infection, which depletes these cells, has been reported to attenuate the manifestations of sarcoidosis...
  33. ncbi Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis
    Yoshikazu Inoue
    Division of Environmental and Occupational Health Sciences and Pulmonary Division, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA
    Am J Respir Crit Care Med 166:765-73. 2002
    ..These data suggest that mast cell-derived bFGF might exert fibrogenic, proliferative effects on smooth muscle cell/myofibroblast-like cells through its receptors...
  34. ncbi Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
    Kevin R Flaherty
    Division of Pulmonary and Critical Care Medicine, Department of Radiology, University of Michigan Health System, 3916 Taubman Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0360, USA
    Am J Respir Crit Care Med 170:904-10. 2004
    ..We conclude that dynamic interactions between clinicians, radiologists, and pathologists improve interobserver agreement and diagnostic confidence...
  35. ncbi A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
    Ganesh Raghu
    Division of Pulmonary Medicine, University of Washington, Seattle 98195, USA
    N Engl J Med 350:125-33. 2004
    ..Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy...
  36. ncbi Respiratory bronchiolitis-interstitial lung disease: long-term outcome
    Joshua Portnoy
    National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206, USA
    Chest 131:664-71. 2007
    ..In this study, we sought to determine the outcome of RB-ILD patients with and without smoking cessation and with and without corticosteroid therapy...
  37. ncbi Nonspecific interstitial pneumonia and systemic sclerosis
    Talmadge E King
    Am J Respir Crit Care Med 165:1578-9. 2002
  38. ncbi High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis
    David A Lynch
    Department of Radiology, and Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box A030, Room 2233 Denver, CO 80262, USA
    Am J Respir Crit Care Med 172:488-93. 2005
    ..High-resolution computed tomography (HRCT) is an integral aspect of the evaluation of patients with suspected idiopathic pulmonary fibrosis (IPF). However, few studies have evaluated its use in a large cohort...
  39. ncbi The clinical course of patients with idiopathic pulmonary fibrosis
    Fernando J Martinez
    University of Michigan, Ann Arbor, Michigan 48109, USA
    Ann Intern Med 142:963-7. 2005
    ..Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse...
  40. ncbi Classification and natural history of the idiopathic interstitial pneumonias
    Dong Soon Kim
    Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, 388 1 Poongnap dong, Songpa Ku, Seoul, Korea, 138 736
    Proc Am Thorac Soc 3:285-92. 2006
    ..However, there is still confusion and controversy over the relationship between idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia...
  41. ncbi Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project
    William D Travis
    Attending Thoracic Pathologist, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Respir Crit Care Med 177:1338-47. 2008
    ..Concern was expressed that NSIP was a "wastebasket" category, difficult to distinguish from other idiopathic interstitial pneumonias...
  42. ncbi Idiopathic interstitial pneumonias: CT features
    David A Lynch
    Department of Radiology, University of Colorado Health Sciences Center, CB A 030, 4200 E Ninth Ave, Denver, CO 80262, USA
    Radiology 236:10-21. 2005
    ..AIP manifests as diffuse lung consolidation and ground-glass opacity. LIP is associated with a CT pattern of ground-glass opacity sometimes associated with perivascular cysts...
  43. ncbi Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate
    Roland Du Bois
    Interstitial Lung Disease Unit, Department of Occupational and Environmental Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UK
    Thorax 62:1008-12. 2007
    ..The histopathological pattern of NSIP can be found in a wide variety of clinical and radiological contexts. This review addresses these and other uncertainties regarding NSIP and UIP...
  44. ncbi Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias
    Michael B Gotway
    Department of Radiology, University of California at San Francisco, and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, USA
    Thorax 62:546-53. 2007
    ..The role of surgical lung biopsy is discussed in the diagnosis of cases when a definite HRCT diagnosis cannot be made...
  45. ncbi Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?
    Kevin R Flaherty
    University of Michigan Health System, Ann Arbor, MI 48109 0360, USA
    Am J Respir Crit Care Med 175:1054-60. 2007
    ..Treatment and prognoses of diffuse parenchymal lung diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis among observers is difficult...
  46. ncbi Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group
    Ronald G Crystal
    Division of Pulmonary and Critical Care Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Am J Respir Crit Care Med 166:236-46. 2002
    ....
  47. ncbi Anticoagulant therapy and idiopathic pulmonary fibrosis
    Brent W Kinder
    Chest 130:302-3. 2006
  48. ncbi Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease
    Brent W Kinder
    Am J Respir Crit Care Med 177:1292-3; author reply 1293. 2008
  49. ncbi Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
    Ana C Zamora
    Hospital Universitario Dr José Eleuterio González, Monterrey, NL, Mexico
    Respir Med 102:150-5. 2008
    ..Treatment of patients with scleroderma ILD for up to 24 months with MMF was generally associated with stable pulmonary function. These data argue for a prospective trial using MMF to treat scleroderma ILD...
  50. ncbi The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis
    Jason S Vourlekis
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Am J Med 116:662-8. 2004
    ..01; 95% confidence interval: 1.68 to 21.45; P = 0.006). CONCLUSION: Pulmonary fibrosis is associated with diminished survival in patients with hypersensitivity pneumonitis...
  51. ncbi Racial disparities in clinical trials
    Talmadge E King
    N Engl J Med 346:1400-2. 2002